A Phase 2 interventional study of ARO-APOC3 and Placebo in Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Completed at 74 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.
Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 26th largest by enrollment of the 145 interventional ones that give a count, is one of 6 that started in 2021, is one of 45 in phase 2, and was the 121st registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 1 more country
Ages 18+
Marea Therapeutics · Sites in United States
Ages 18–75
The Miriam Hospital · Sites in United States
Ages 18–69
Marea Therapeutics · Sites in United States, Australia, Canada and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 51 · Phase 3 30 · Phase 4 13
First in 1977; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 229 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 52 across the 145 interventional studies, 130 across the 3 observational. Of the 124 that completed or were terminated, 57 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 150 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 8 studies filed under Hypertriglyceridemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertriglyceridemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT05464784MediciNovaMN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | 2026-12-31 |
| NCT07269210Eli Lilly and CompanyA Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | 2027-03 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertriglyceridemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: additional inclusion/exclusion criteria may apply per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a total of 2 placebo SC injections on Day 1 and Week 12 for a total of 2 injections.
Drug: Placebo
Participants received a total of 2 ARO-APOC3 10 mg SC injections on Day 1 and Week 12 for a total of 2 injections.
Drug: ARO-APOC3
Participants received a total of 2 ARO-APOC3 25 mg SC injections on Day 1 and Week 12 for a total of 2 injections.
Drug: ARO-APOC3
Participants received a total of 2 ARO-APOC3 50 mg SC injections on Day 1 and Week 12 for a total of 2 injections.
Drug: ARO-APOC3
2 doses of ARO-APOC3 by subcutaneous (sc) injection
calculated volume to match active treatment by sc injection
Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting TG
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in ApoC-III
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting HDL-C
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting Total ApoB
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)
LDL-C analyses used both Martin-Hopkins methodology and ultracentrifugation. The Martin-Hopkins formula is a method for calculating LDL-C that improves accuracy by using an adjustable factor for estimating very-low-density lipoprotein (VLDL) cholesterol cholesterol based on triglyceride and non-HDL cholesterol levels.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting LDL-C
LDL-C analyses used both Martin-Hopkins methodology (MHM) and ultracentrifugation (UC). The Martin-Hopkins formula is a method for calculating LDL-C that improves accuracy by using an adjustable factor for estimating very-low-density lipoprotein (VLDL) cholesterol cholesterol based on triglyceride and non-HDL cholesterol levels.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Change From Baseline in Plasma Concentrations of ARO-APOC3 Over TimeThrough Week 12
Time frame: Day 1: pre-dose, 15 minutes, 1, 3, 6, 24 hours post-dose; Week 12: pre-dose, 15 minutes, 1, 3, 6, 24 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction. TEAEs are AEs that occur following investigational product (IP) administration or a pre-existing condition exacerbated following IP administration.
Time frame: From first dose of study drug up to Week 48
There were 76 study centers in 8 countries (Australia, Canada, Germany, Hungary, The Netherlands, New Zealand, Poland, and the United States \[US\]).
| Milestone | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Started | 62 | 55 | 55 | 57 |
| Completed | 58 | 50 | 52 | 53 |
| Not completed | 4 | 5 | 3 | 4 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Other, not specified | 0 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 0 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG) | -17.2 ± 5.27 | -66.0 ± 5.61 | -70.2 ± 5.51 | -74.2 ± 5.44 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 7.2 ± 4.61 | -63.3 ± 4.88 | -79.5 ± 4.81 | -77.6 ± 4.72 |
| Week 8 | -0.7 ± 5.19 | -54.0 ± 5.46 | -73.2 ± 5.45 | -72.8 ± 5.34 |
| Week 12 | -7.3 ± 7.05 | -53.9 ± 7.35 | -64.9 ± 7.29 | -70.3 ± 7.24 |
| Week 16 | -2.9 ± 5.91 | -70.5 ± 6.32 | -80.1 ± 6.17 | -76.3 ± 6.15 |
| Week 20 | 2.4 ± 6.66 | -67.7 ± 7.07 | -75.3 ± 7.02 | -75.6 ± 6.91 |
| Week 24 | -17.2 ± 5.27 | -66.0 ± 5.61 | -70.2 ± 5.51 | -74.2 ± 5.44 |
| Week 28 | -11.7 ± 5.83 | -60.0 ± 6.33 | -70.3 ± 6.23 | -70.8 ± 6.11 |
| Week 36 | -7.6 ± 9.08 | -37.7 ± 9.70 | -64.0 ± 9.54 | -53.6 ± 9.35 |
| Week 48 | -6.6 ± 7.71 | -31.4 ± 8.20 | -58.0 ± 8.15 | -53.4 ± 7.97 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III | 114.2 ± 73.08 | -69.6 ± 76.90 | -73.7 ± 76.04 | -79.4 ± 73.19 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 209.3 ± 73.06 | -67.3 ± 76.79 | -84.4 ± 76.00 | -84.6 ± 73.12 |
| Week 8 | 146.3 ± 73.06 | -59.8 ± 76.76 | -78.8 ± 76.03 | -79.9 ± 73.14 |
| Week 12 | 122.2 ± 73.13 | -55.5 ± 76.79 | -71.8 ± 76.04 | -73.2 ± 73.21 |
| Week 16 | 134.4 ± 73.09 | -77.1 ± 76.90 | -86.4 ± 76.04 | -87.1 ± 73.25 |
| Week 20 | 118.8 ± 73.11 | -71.7 ± 76.87 | -81.2 ± 76.13 | -84.0 ± 73.26 |
| Week 24 | 114.2 ± 73.08 | -69.6 ± 76.90 | -73.7 ± 76.04 | -79.4 ± 73.19 |
| Week 28 | 140.2 ± 73.06 | -64.4 ± 76.89 | -71.9 ± 76.09 | -74.7 ± 73.21 |
| Week 36 | 152.0 ± 73.13 | -50.2 ± 76.92 | -60.9 ± 76.12 | -59.9 ± 73.21 |
| Week 48 | 135.8 ± 73.14 | -34.5 ± 76.89 | -49.6 ± 76.16 | -48.3 ± 73.25 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) | -1.5 ± 3.76 | -29.4 ± 4.04 | -28.4 ± 3.90 | -21.7 ± 3.83 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 6.3 ± 3.35 | -27.0 ± 3.57 | -34.7 ± 3.46 | -26.1 ± 3.37 |
| Week 8 | 4.5 ± 3.77 | -19.7 ± 4.00 | -30.7 ± 3.92 | -20.7 ± 3.82 |
| Week 12 | 1.4 ± 4.54 | -19.3 ± 4.77 | -30.0 ± 4.67 | -22.3 ± 4.61 |
| Week 16 | 1.8 ± 3.73 | -27.9 ± 4.00 | -37.8 ± 3.87 | -23.7 ± 3.81 |
| Week 20 | 5.7 ± 3.96 | -26.7 ± 4.22 | -34.6 ± 4.13 | -22.9 ± 4.04 |
| Week 24 | -1.5 ± 3.76 | -29.4 ± 4.04 | -28.4 ± 3.90 | -21.7 ± 3.83 |
| Week 28 | -2.3 ± 3.82 | -27.4 ± 4.14 | -31.3 ± 4.02 | -24.0 ± 3.92 |
| Week 36 | -0.3 ± 4.57 | -19.2 ± 4.91 | -23.8 ± 4.78 | -13.1 ± 4.65 |
| Week 48 | 0.5 ± 4.58 | -10.0 ± 4.92 | -23.0 ± 4.83 | -13.5 ± 4.69 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) | 10.6 ± 5.87 | 54.2 ± 6.32 | 62.8 ± 6.09 | 67.6 ± 6.00 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 4.3 ± 5.48 | 53.4 ± 5.86 | 76.2 ± 5.67 | 88.1 ± 5.56 |
| Week 8 | 6.2 ± 5.45 | 45.4 ± 5.79 | 73.5 ± 5.66 | 67.7 ± 5.54 |
| Week 12 | 11.3 ± 5.50 | 39.9 ± 5.81 | 60.2 ± 5.66 | 62.5 ± 5.59 |
| Week 16 | 5.7 ± 5.78 | 66.2 ± 6.23 | 87.1 ± 5.99 | 82.6 ± 5.94 |
| Week 20 | 8.8 ± 6.20 | 61.2 ± 6.63 | 78.7 ± 6.48 | 81.2 ± 6.36 |
| Week 24 | 10.6 ± 5.87 | 54.2 ± 6.32 | 62.8 ± 6.09 | 67.6 ± 6.00 |
| Week 28 | 10.2 ± 5.55 | 48.2 ± 6.00 | 67.2 ± 5.81 | 68.0 ± 5.70 |
| Week 36 | 11.7 ± 5.83 | 34.5 ± 6.29 | 51.1 ± 6.09 | 47.2 ± 5.95 |
| Week 48 | 6.1 ± 5.40 | 23.5 ± 5.80 | 32.4 ± 5.65 | 37.8 ± 5.51 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB) | 8.0 ± 5.85 | 6.0 ± 6.31 | -5.3 ± 6.06 | 0.7 ± 6.01 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 16.2 ± 6.70 | -2.3 ± 7.10 | -9.0 ± 6.95 | -1.9 ± 6.84 |
| Week 8 | 16.0 ± 4.74 | -0.8 ± 4.97 | -7.2 ± 4.89 | 1.5 ± 4.82 |
| Week 12 | 4.2 ± 3.70 | 0.5 ± 3.80 | -11.2 ± 3.74 | -1.3 ± 3.73 |
| Week 16 | 5.3 ± 4.13 | -0.8 ± 4.34 | -13.1 ± 4.22 | -0.6 ± 4.20 |
| Week 20 | 1.6 ± 3.98 | -0.7 ± 4.17 | -10.3 ± 4.10 | 4.4 ± 4.06 |
| Week 24 | 8.0 ± 5.85 | 6.0 ± 6.31 | -5.3 ± 6.06 | 0.7 ± 6.01 |
| Week 28 | 3.9 ± 3.70 | -1.3 ± 3.92 | -6.0 ± 3.83 | 0.6 ± 3.79 |
| Week 36 | 8.9 ± 4.10 | -0.4 ± 4.35 | 2.5 ± 4.24 | 8.5 ± 4.17 |
| Week 48 | 5.7 ± 4.06 | 6.4 ± 4.28 | -0.2 ± 4.21 | 2.4 ± 4.14 |
LDL-C analyses used both Martin-Hopkins methodology and ultracentrifugation. The Martin-Hopkins formula is a method for calculating LDL-C that improves accuracy by using an adjustable factor for estimating very-low-density lipoprotein (VLDL) cholesterol cholesterol based on triglyceride and non-HDL cholesterol levels.
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Martin-Hopkins methodology | -5.5 ± 123.7 | 301.9 ± 128.17 | -15.4 ± 120.30 | 2.0 ± 123.04 |
| Ultracentrifugation | 18.0 ± 10.48 | 49.0 ± 11.06 | 43.7 ± 10.76 | 78.2 ± 10.60 |
LDL-C analyses used both Martin-Hopkins methodology (MHM) and ultracentrifugation (UC). The Martin-Hopkins formula is a method for calculating LDL-C that improves accuracy by using an adjustable factor for estimating very-low-density lipoprotein (VLDL) cholesterol cholesterol based on triglyceride and non-HDL cholesterol levels.
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| MHM Week 4 | -29.3 ± 123.78 | 267.3 ± 128.13 | -13.5 ± 120.28 | 0.6 ± 123.00 |
| MHM Week 8 | -11.3 ± 123.74 | 297.4 ± 128.11 | -11.7 ± 120.29 | 5.3 ± 123.01 |
| MHM Week 12 | -13.6 ± 123.75 | 300.7 ± 128.12 | -17.3 ± 120.29 | 3.2 ± 123.02 |
| MHM Week 16 | -14.3 ± 123.72 | 340.3 ± 128.15 | -20.4 ± 120.29 | 5.6 ± 123.04 |
| MHM Week 20 | -7.3 ± 123.72 | 306.7 ± 128.15 | -17.4 ± 120.31 | 4.9 ± 123.05 |
| MHM Week 24 | -5.5 ± 123.67 | 301.9 ± 128.17 | -15.4 ± 120.30 | 2.0 ± 123.04 |
| MHM Week 28 | -12.1 ± 123.68 | 283.2 ± 128.20 | -12.1 ± 120.34 | -4.7 ± 123.06 |
| MHM Week 36 | -5.5 ± 123.73 | 254.7 ± 128.28 | -0.7 ± 120.38 | 1.6 ± 123.10 |
| MHM Week 48 | -11.5 ± 123.77 | 286.5 ± 128.34 | -9.0 ± 120.44 | -5.3 ± 123.12 |
| UC Week 4 | 4.4 ± 9.65 | 50.3 ± 10.10 | 47.3 ± 9.88 | 69.1 ± 9.67 |
| UC Week 8 | 15.8 ± 10.44 | 49.8 ± 10.92 | 45.8 ± 10.73 | 65.4 ± 10.51 |
| UC Week 12 | 17.1 ± 10.17 | 50.9 ± 10.57 | 36.0 ± 10.38 | 65.8 ± 10.22 |
| UC Week 16 | 19.3 ± 12.14 | 62.6 ± 12.80 | 41.7 ± 12.46 | 87.1 ± 12.31 |
| UC Week 20 | 16.8 ± 11.79 | 62.7 ± 12.38 | 42.3 ± 12.16 | 85.9 ± 11.93 |
| UC Week 24 | 18.0 ± 10.48 | 49.0 ± 11.06 | 43.7 ± 10.76 | 78.2 ± 10.60 |
| UC Week 28 | 15.4 ± 10.14 | 50.8 ± 10.76 | 42.3 ± 10.51 | 61.6 ± 10.30 |
| UC Week 36 | 18.4 ± 9.89 | 35.5 ± 10.47 | 51.5 ± 10.20 | 61.3 ± 9.97 |
| UC Week 48 | 21.3 ± 10.73 | 33.5 ± 11.36 | 34.4 ± 11.14 | 44.6 ± 10.87 |
| ng/mL | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|
| Day 1, Pre-Dose | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Day 1, 15 Minutes Post-Dose | 10.258 ± 12.4741 | 21.207 ± 21.7982 | 34.352 ± 27.3986 |
| Day 1, 1 Hour Post-Dose | 18.124 ± 18.1760 | 37.396 ± 27.9849 | 58.508 ± 29.0222 |
| Day 1, 3 Hours Post-Dose | 20.217 ± 16.8127 | 50.596 ± 53.3270 | 58.493 ± 30.5510 |
| Day 1, 6 Hours Post-Dose | 17.147 ± 14.6145 | 51.813 ± 44.2610 | 64.019 ± 26.3749 |
| Day 1, 24 Hours Post-Dose | 7.921 ± 16.9181 | 10.316 ± 11.5852 | 11.587 ± 6.4288 |
| Week 12, Pre-Dose | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Week 12, 15 Minutes Post-Dose | 10.188 ± 9.4024 | 23.576 ± 29.1713 | 38.500 ± 32.4047 |
| Week 12, 1 Hour Post-Dose | 17.090 ± 12.7636 | 35.513 ± 26.5491 | 57.939 ± 26.8754 |
| Week 12, 3 Hours Post-Dose | 15.101 ± 9.5156 | 42.591 ± 39.0808 | 65.482 ± 44.5255 |
| Week 12, 6 Hours Post-Dose | 11.131 ± 6.6894 | 56.230 ± 52.4345 | 73.444 ± 42.1339 |
| Week 12, 24 Hours Post-Dose | 3.143 ± 5.5271 | 6.241 ± 7.5820 | 12.125 ± 8.5500 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction. TEAEs are AEs that occur following investigational product (IP) administration or a pre-existing condition exacerbated following IP administration.
| Participants | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| All TEAEs | 43 | 43 | 36 | 49 |
| Treatment-related TEAEs | 8 | 13 | 8 | 10 |
| Serious TEAEs | 10 | 4 | 2 | 7 |
| TEAEs leading to study drug discontinuation | 0 | 1 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
| percentage change | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Week 4 | 7.0 ± 3.88 | -65.1 ± 4.04 | -82.9 ± 3.94 | -83.2 ± 3.81 |
| Week 8 | 4.7 ± 4.19 | -57.3 ± 4.36 | -77.2 ± 4.26 | -78.7 ± 4.14 |
| Week 12 | 0.0 ± 4.79 | -53.2 ± 4.97 | -70.3 ± 4.84 | -72.2 ± 4.74 |
| Week 16 | 2.8 ± 3.94 | -74.8 ± 4.13 | -84.9 ± 4.00 | -86.3 ± 3.92 |
| Week 20 | 7.8 ± 4.60 | -69.9 ± 4.81 | -79.7 ± 4.72 | -82.6 ± 4.60 |
| Week 24 | -0.8 ± 4.29 | -68.1 ± 4.51 | -72.1 ± 4.37 | -78.2 ± 4.26 |
| Week 28 | -2.2 ± 4.19 | -63.0 ± 4.42 | -70.2 ± 4.31 | -73.2 ± 4.19 |
| Week 36 | 0.2 ± 4.98 | -48.5 ± 5.23 | -59.1 ± 5.10 | -58.3 ± 4.95 |
| Week 48 | 5.6 ± 6.19 | -33.7 ± 6.48 | -48.0 ± 6.37 | -46.8 ± 6.19 |
Collected over Up to 48 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo, Day 1 and Week 12 | 0/61 (0%) | 10/61 (16.4%) | 44/61 (72.1%) |
| ARO-APOC3 10 mg | 0/54 (0%) | 4/54 (7.4%) | 44/54 (81.5%) |
| ARO-APOC3 25 mg | 0/55 (0%) | 2/55 (3.6%) | 36/55 (65.5%) |
| ARO-APOC3 50 mg | 0/56 (0%) | 7/56 (12.5%) | 50/56 (89.3%) |
| Event | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/61 | 1/54 | 0/55 | 0/56 |
| EnteritisGastrointestinal disorders | 0/61 | 1/54 | 0/55 | 0/56 |
| ConcussionInjury, poisoning and procedural complications | 0/61 | 1/54 | 0/55 | 0/56 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/61 | 1/54 | 0/55 | 1/56 |
| Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/61 | 1/54 | 0/55 | 0/56 |
| COVID-19Infections and infestations | 1/61 | 0/54 | 1/55 | 0/56 |
| Pneumonia bacterialInfections and infestations | 0/61 | 0/54 | 1/55 | 0/56 |
| SepsisInfections and infestations | 0/61 | 0/54 | 1/55 | 0/56 |
| Pancreatitis acuteGastrointestinal disorders | 1/61 | 0/54 | 0/55 | 1/56 |
| Small intestinal obstructionGastrointestinal disorders | 0/61 | 0/54 | 0/55 | 1/56 |
| Event | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg |
|---|---|---|---|---|
| COVID-19Infections and infestations | 9/61 | 11/54 | 9/55 | 9/56 |
| HeadacheNervous system disorders | 3/61 | 8/54 | 6/55 | 2/56 |
| Upper respiratory tract infectionInfections and infestations | 4/61 | 5/54 | 4/55 | 7/56 |
| Urinary tract infectionInfections and infestations | 6/61 | 6/54 | 1/55 | 4/56 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 3/61 | 1/54 | 4/55 | 6/56 |
| Back painMusculoskeletal and connective tissue disorders | 1/61 | 5/54 | 1/55 | 1/56 |
| HypertensionVascular disorders | 4/61 | 0/54 | 2/55 | 5/56 |
| DiarrhoeaGastrointestinal disorders | 5/61 | 3/54 | 1/55 | 1/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/61 | 3/54 | 1/55 | 4/56 |
| BronchitisInfections and infestations | 2/61 | 4/54 | 0/55 | 4/56 |
| Age, Continuous(years) | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 55.8 ± 11.22 | 52.9 ± 9.55 | 56.0 ± 10.64 | 54.3 ± 11.00 | 54.9 ± 10.59 |
| Sex: Female, Male(Participants) | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg | Total |
|---|---|---|---|---|---|
| Female | 15 | 8 | 12 | 16 | 51 |
| Male | 47 | 47 | 43 | 41 | 178 |
| Ethnicity (NIH/OMB)(Participants) | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 7 | 6 | 33 |
| Not Hispanic or Latino | 48 | 47 | 48 | 51 | 194 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo, Day 1 and Week 12 | ARO-APOC3 10 mg | ARO-APOC3 25 mg | ARO-APOC3 50 mg | Total |
|---|---|---|---|---|---|
| White | 56 | 48 | 48 | 53 | 205 |
| Black or African American | 1 | 2 | 3 | 1 | 7 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 3 | 1 | 2 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 0 | 2 |
| Unknown | 0 | 1 | 0 | 0 | 1 |
| Other, Not Specified | 1 | 3 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Mar 2023, 21 months.
Results were first posted in Mar 2026, 3 years after primary completion. A results delay was requested in Mar 2024.
Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plozasiran